ABBOTT PARK, Ill., Aug. 30, 2017 — Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occurs in approximately 80,000 pre-term infants in the U.S. each year.

Cardiac arrest suffered in predominately black neighborhoods is associated with worse rates of survival and bystander treatment, despite quicker emergency medical services (EMS) response times, according to a new study in JAMA Cardiology.

Apparently, it’s possible to have too much of a good thing. At least that’s what researchers are suggesting about high-density lipoprotein (HDL) cholesterol, widely known as the “good” type of cholesterol.

Donor hearts with left ventricular systolic dysfunction (LVSD) can be revived and transplanted as successfully as other hearts, according to a study in the Journal of the American College of Cardiology.

Abbot Laboratories released a software update Aug. 23 for pacemaker and CRT-P devices. The Food & Drug Administration released a recommendation for patients to visit their healthcare providers to discuss vulnerability and updates.

The origin story of warfarin has been detailed previously—but it’s worth revisiting because it’s so darn intriguing.

Ablation led to greater quality of life improvements than drugs in patients with atrial fibrillation (AFib), according to results presented Aug. 29 at the European Society of Cardiology Congress.

Survival with favorable quality of life improved among patients with refractory out-of-hospital ventricular fibrillation (VF)/ventricular tachycardia (VT) cardiac arrest when they were quickly taken to a cardiac catheterization laboratory (CCL) for extracorporeal life support (ECLS) and revascularization, as opposed to being treated with prolonged resuscitation efforts at the scene of their heart attack, according to new research.